PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32197603-3	2020	Here, Escherichia coli (E. coli) JM109 cells over-expressing the recombinant human FMO3 (flavin-containing monooxygenase isoform 3) were used for the conversions of clomiphene, dasatinib, GSK5182 and tozasertib to their corresponding N-oxide metabolites.	GSK5182	188-195	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	83-87	
32197603-3	2020	Here, Escherichia coli (E. coli) JM109 cells over-expressing the recombinant human FMO3 (flavin-containing monooxygenase isoform 3) were used for the conversions of clomiphene, dasatinib, GSK5182 and tozasertib to their corresponding N-oxide metabolites.	GSK5182	188-195	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	89-130	
32197603-6	2020	In addition, FMO3 shows high regio-selectivity in metabolizing GSK5182 where only the (Z) isomer is monooxygenated.	GSK5182	63-70	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	13-17	
32197603-7	2020	CONCLUSIONS: The study shows the successful use of human FMO3-based whole-cell as a biocatalyst for the efficient synthesis of drug metabolites including regio-selective reactions involving GSK5182, a new candidate against type 2 diabetes mellitus.	GSK5182	190-197	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	57-61	
29959872-3	2018	The purpose of this study was to investigate the effect of the three common polymorphic variants of hFMO3 (V257M, E158K and E308G) on the metabolism and clearance of three structurally similar compounds: tamoxifen (breast cancer medication), clomiphene (infertility medication) and GSK5182 (antidiabetic lead molecule).	GSK5182	282-289	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	100-105